

Dear Mr. Glickman,

The program in the study of opiate addiction at the New York Medical College had its inception in 1960 with the opening of a narcotic treatment service at Metropolitan Hospital. Since that time, various treatments ~~and~~ have been assessed, including psychotherapy, social and group therapies, therapeutic community, etc. A special Substance Abuse Study center was created (under the direction of Dr. Richard Brotman) and this unit has studied <sup>d</sup> the sociological aspects of substance abuse, contributing to the understanding of the typology of addicts, the spread of addiction ~~in~~ in the schools and campuses, etc.

Beginning in 1965, a specific study program focussed on the use of pharmacological treatments was developed, following the ~~the~~ legal and ethical breakthroughs initiated by the ~~the~~ pioneering efforts of Drs. Vincent Dole and Marie Nyswander. We undertook studies of methadone, and when other substances for the treatment of opiate addiction, <sup>became available;</sup> decided to assess <sup>their</sup> the role ~~of~~ and merits <sup>and benefits</sup> of cyclazocine, naloxone, <sup>and</sup> tybamate, <sup>as well as methadone.</sup> ↑

With the assistance of the New York State Narcotic Control Commission, the City of New York and the National Institutes of Health <sup>Health</sup> we have been able to assemble ~~a group of~~ scientists interested in opiate addiction and are carrying out a variety of studies. Some have already been reported, and copies of those summaries are enclosed for your information. At present, we are treating 60 patients in our out-patient group, and <sup>o</sup> another 22 in the in-patient center. The ~~the~~ out-patient group has been limited largely by our inability to <sup>obtain support to</sup> establish a community based facility for aftercare and rehabilitation.

Some of <sup>of</sup> The studies in progress ~~are many and~~ may be described under the following titles: Duration of antagonism to heroin ~~to~~ <sup>of</sup> chronic oral methadone; <sup>of</sup> Specificity of antagonism to heroin of naloxone; Duration

*maximum of*  
of action and clinical efficacy of naloxone in/opiate addiction;

Comparison of the CNS effects of opiates and antagonists;

Typology of addicts: Significance for therapy choice in

cyclazocine and methadone treatments

Application of tybamate in the barbiturate withdrawal syndrome

~~Role~~

Behavioral and EEG effects of marijuana and ~~THC-1-9~~ *Tetrahydrocannabinol*

Behavioral effects of chronic marijuana use

measurable

Is there a withdrawal phenomenon with marijuana use ?

I trust this will be sufficient to give you an overview of the programs. The Director of the programs is the Professor of Psychiatry and Chairman of the Department, Dr. Alfred M. Freedman. *I am*  
~~My own position is that of Project Director and Director of the Division of Biological Psychiatry, of the Department of Psychiatry. I will~~  
*and while I will*  
be pleased to answer your enquiries, although if you intend to visit our center, it would be ~~most~~ *more* useful for ~~such arrangements~~ *any visits to this center* to be made ~~at the time that Dr. Freedman is available.~~ *when*

Sincerely yours,

Encl:

JAMA - cycl + meth

Amf - study of opiate R

Naloxone

Tybamate report

Zans - heroin challenges

Research - cyclaz. Typol of addicts. (APA-69)